<DOC>
	<DOC>NCT00426816</DOC>
	<brief_summary>This study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia</brief_summary>
	<brief_title>To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>Male 1864 years of age (inclusive), Diagnosis of primary insomnia who have had symptoms for at least three months. Any clinically significant unstable medical or surgical condition (treated or untreated). Any history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>primary insomnia</keyword>
	<keyword>PSG sleep recordings</keyword>
	<keyword>daytime cognitive function</keyword>
	<keyword>Insomnia</keyword>
	<keyword>SB-649868</keyword>
</DOC>